Adavosertib
- Generic Name
- Adavosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32N8O2
- CAS Number
- 955365-80-7
- Unique Ingredient Identifier
- K2T6HJX3I3
- Background
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Adavosertib and Gemcitabine in Advanced Pancreatic
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- James Cleary, MD, PhD
- Registration Number
- NCT05212025
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
- Conditions
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT04959266
- Locations
- 🇪🇸
Research Site, Malaga, Spain
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT04949425
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 109
- Registration Number
- NCT04590248
- Locations
- 🇪🇸
Research Site, Pozuelo de Alarcón, Spain
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
- Conditions
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Distal Esophagus AdenocarcinomaMetastatic Esophageal AdenocarcinomaPathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT04460937
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439227
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT04197713
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT03668340
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Adavosertib with or Without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT03579316
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Prostate Cancer Biomarker Enrichment and Treatment Selection
- Conditions
- Interventions
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 200
- Registration Number
- NCT03385655
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.